Scientists map ulcerative colitisScientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments. more ➔
COVID-19: Roche and Regeneron join forcesRoche and Regeneron have signed an manufacturing and distribution agreement on Regeneron’s Phase II therapeutic antibody for the treatment of COVID-19. more ➔
Aicuris to launch AiCubator to fight AMRAntinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference. more ➔
Cell-based vaccination vs mortality-reducing therapies Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging … more ➔
AI predicts mutations underlying neurological diseases Using data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease. more ➔
F2G bags €50.8m financing to advance olorofimUK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors. more ➔
Evotec receives $8.4m CARB-X fundingEvotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic. more ➔
The new role of communications in times of coronaCOVID-19 has put life science research companies into the limelight. An Interview with Raimund Gabriel, founder and managing director MC Services AG, on the role of corporate communications in the corona … more ➔
The end of partnering events as we know themAn ongoing crisis and evolving new working habits of industry executives call for an entirely new and up-to-date partnering format. Workarounds such as moving a partnering event’s scheduled one-on-one … more ➔
BioNTech and Fosun Pharma kick off Chinese COVID-19 trialsBioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials. more ➔
